That after they applied for EU emergency approval for the shot.
It follows similar steps in the United States and Britain.
In their pursuit of a European launch, Pfizer and BioNTech are neck-and-neck with rival Moderna.
Moderna said on Monday it would ask the EU regulator to recommend conditional approval for its shot.
U.S. drugmaker Pfizer and Germany's BioNTech reported final trial results on November 18th.
They showed their vaccine candidate was 95% effective in preventing COVID-19, with no major safety concerns.
Any clearance in the EU and U.S. will be "conditional" or for "emergency use".
That means developers must continue trials and provide more results as they emerge.
The European Commission said on Monday that it is likely to give the final authorisation for the roll-out of vaccines days after the EU drug regulator approves them.
The EMA said on Tuesday that it experts to have enough data from drugmakers Pfizer and Moderna to complete its reviews by December 29th and January 12th, respectively, at the latest.
An effective immunisation is seen as the main weapon against the pandemic, which has claimed more than 1.4 million lives.
